Clinical Trials Browser

INDUSTRY × Interventional × Lethal Congenital Contracture Syndrome 2 × Clear all

NCT07070232 2026-03-12

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Phase 1/2 Recruiting

DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2025-10-22

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 1 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Phase 1 Completed

44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

162 enrolled 11 charts

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Phase 1 Completed

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2